M&A / Deals Parexel buys Vitrana to boost patient safety toolkit PharmaphorumContract research organisation Parexel has bought Vitrana and its AI-powered pharmacovigilance platform for an undisclosed sum.Read full story pharminent April 30, 2026 (Last updated: May 1, 2026) Pharmaphorum Contract research organisation Parexel has bought Vitrana and its AI-powered pharmacovigilance platform for an undisclosed sum. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: UniQure, in ‘symbolic’ win, to seek UK approval of Huntington’s gene therapyNext: Merck still sees ‘compelling’ outlook for Terns leukemia drug Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
